| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 07/12/2007 | WO2006129160A3 Stable aqueous oral solution of risperidone |
| 07/12/2007 | WO2006123244A3 Carbamate derivatives as positive allosteric modulators of metabotropic glutamate receptors |
| 07/12/2007 | WO2006123243A3 Pharmaceutical dosage forms comprising escitalopram in form of granules |
| 07/12/2007 | WO2006120576A3 Immunogens for meningitidis-a vaccines |
| 07/12/2007 | WO2006116458B1 Modified oligoribonucleotide analogs with enhances immunostimulatory activity |
| 07/12/2007 | WO2006113579A3 Tumor inhibition by modulating sprouty expression or activity |
| 07/12/2007 | WO2006112717A3 Nutritional supplement for a category of hiv patients |
| 07/12/2007 | WO2006107806A3 Stannsoporfin compositions and administration |
| 07/12/2007 | WO2006107478A3 Crystalline sodium salt of an hiv integrase inhibitor |
| 07/12/2007 | WO2006105215A3 The use of a spin trap for enhancing retinal cell survival and treating retinal degenerative diseases |
| 07/12/2007 | WO2006103537A3 Treatment of epilepsy with non-imidazole alkylamines histamine h3-receptor ligands |
| 07/12/2007 | WO2006098834A9 Crystalline forms of ziprasidone mesylate |
| 07/12/2007 | WO2006096529A3 Genes involved in neurodegenerative conditions |
| 07/12/2007 | WO2006093514A3 Aryl and arylalkylenyl substituted thiazoloquinolines and thiazolonaphthyridines |
| 07/12/2007 | WO2006091964A3 Regulators of protein misfolding and aggregation and methods of using the same |
| 07/12/2007 | WO2006091798A3 Vaccines and methods for prevention and treatment of drug-resistant hiv-1 and hepatitis b virus |
| 07/12/2007 | WO2006091795A3 METHODS AND COMPOSITIONS INVOLVING EXPRESSION OF α1C SUBUNIT OF L-TYPE CALCIUM CHANNELS IN SMOOTH MUSCLE CELLS |
| 07/12/2007 | WO2006091716A3 Nitric oxide enhancing diuretic compounds, compositions and methods of use |
| 07/12/2007 | WO2006089301A3 Diaminophenothiazine compositions and uses thereof |
| 07/12/2007 | WO2006076580A3 A method of modulating t cell functioning |
| 07/12/2007 | WO2006074957A9 Substituted aminomethylene sulphonamides, production and use thereof as medicaments |
| 07/12/2007 | WO2006072113A3 Therapeutic composition |
| 07/12/2007 | WO2006058723A8 New pyridothienopyrimidine derivatives |
| 07/12/2007 | WO2006058201A3 Heterocyclic and bicyclic compounds, compositions and methods |
| 07/12/2007 | WO2006050836A3 Ophthalmic emulsions containing prostaglandins |
| 07/12/2007 | WO2006050170A3 Medical devices containing rapamycin analogs |
| 07/12/2007 | WO2006029075A3 Fibrate compounds having ppar agonist activity |
| 07/12/2007 | WO2006024044A3 Composition and method for altering levels of or sensitivity to adenosine with analogs of dehydroepiandrostone |
| 07/12/2007 | WO2006009718A3 Methods for treating or preventing erectile dysfunction or urinary incontinence |
| 07/12/2007 | WO2005117545A3 Nitric oxide dioxygenase inhibitors |
| 07/12/2007 | WO2005107455A3 Antimicrobial coating for inhibition of bacterial adhesion and biofilm formation |
| 07/12/2007 | WO2005027962A3 4’-thionucleosides and oligomeric compounds |
| 07/12/2007 | WO2004112687A3 Antiviral acylguanidine compounds and methods |
| 07/12/2007 | WO2004104166A3 Administration of hyaluronic acid to enhance the function of transplanted stem cells |
| 07/12/2007 | WO2003077723A3 Methods and devices for detection and therapy of atheromatous plaque |
| 07/12/2007 | US20070161794 Slurrying aripiprazole in a solvent (acetone), heating and isolating anhydrous aripiprazole Form II from the slurry |
| 07/12/2007 | US20070161789 Inhibitors of serine proteases, particularly HCV NS3-NS4A protease |
| 07/12/2007 | US20070161787 (1S)-1,5-anhydro-1-[3-(1-benzothien-2-ylmethyl)phenyl-D-glucitol and derivatives are Na+-glucose cotransporter inhibitors and are used to treat diabetes and related diseases such as insulin-resistance and obesity |
| 07/12/2007 | US20070161712 Genes encoding epsilon lycopene cyclase and method for producing bicyclic epsilon carotene |
| 07/12/2007 | US20070161711 Process for producing pellets for pharmaceutical compositions |
| 07/12/2007 | US20070161710 Bone targeting compounds for delivering agents to bone for interaction therewith |
| 07/12/2007 | US20070161709 Amorphous tamsulosin hydrochloride |
| 07/12/2007 | US20070161708 Polymorphs of sodium 4-[(4-chloro-2-hydroxybenzoyl) amino] butanoate |
| 07/12/2007 | US20070161707 Pharmaceutical uses for alpha2delta ligands |
| 07/12/2007 | US20070161706 Pharmaceutical uses for alpha2delta ligands |
| 07/12/2007 | US20070161705 Use of highly concentrated compositions of selected n-3 fatty acids for the treatment of central nervous system disturbances |
| 07/12/2007 | US20070161704 Pharmaceutical composition useful for treating chronic myeloid leukemia |
| 07/12/2007 | US20070161703 insecticides; act on calcium ion channels; antagonist of the toxic effects of insecticides in humans; 6S-acetyl-4R,5R-dimethyl-1R(10S)-epoxy-2R-hy-droxy-7R-acetoxydecahydro naphthalene; isolated from the coral Cnidarian Rhytisma fulvum |
| 07/12/2007 | US20070161702 Abca1 stabilizer |
| 07/12/2007 | US20070161701 4-oxo-4,5-dihydro-furan-2-carboxylic acid derivatives and methods of treatment of metabolic-related disorders thereof |
| 07/12/2007 | US20070161700 Inhibitor for the formation of y-secretase complex |
| 07/12/2007 | US20070161699 Method of preventing or treating glaucoma |
| 07/12/2007 | US20070161698 Modulators of CRTH2 Activity |
| 07/12/2007 | US20070161697 Hydrazide type compounds and the use thereof in pharmaceutical compositions for the treatment of cardiovascular diseases |
| 07/12/2007 | US20070161696 Methods of using and compositions comprising selective cytokine inhibitory drugs for treatment, modification and management of pain |
| 07/12/2007 | US20070161695 Hydroisoindoline tachykinin receptor antagonists |
| 07/12/2007 | US20070161694 Use of indirubin as a dietary supplement |
| 07/12/2007 | US20070161693 6-oxa-2-azabicyclo[3.2.0]heptane-3,7-dione's as proteasome inhibitors, used to treat conditions mediated directly by the proteolytic function of the proteasome such as muscle wasting |
| 07/12/2007 | US20070161692 Conformationally restricted polyamine analogs as disease therapies |
| 07/12/2007 | US20070161691 Modified-protein formation inhibitor |
| 07/12/2007 | US20070161690 Compounds and methods for inhibiting the interaction of BCL proteins with binding partners |
| 07/12/2007 | US20070161689 Indoles having anti-diabetic activity |
| 07/12/2007 | US20070161687 1,2,4-Oxadiazole benzoic acid compositions and their use for nonsense suppression and the treatment of disease |
| 07/12/2007 | US20070161686 Cyclopropylmethyl-{3-methoxy-4-[5-(5-methyl-3-phenyl-isoxazol-4-yl)-[1,3,4]oxadiazol-2-yl]-phenyl}-amine; -{3-Methoxy-4-[5-(5-methyl-3-phenyl-isoxazol-4-yl)-[1,3,4]oxadiazol-2-yl]-phenyl}-thiomorpholine; useful for the treatment of cognitive disorders like Alzheimer's disease |
| 07/12/2007 | US20070161685 Cholesteryl ester transfer protein (CETP) inhibitors; atherosclerosis and cardiovascular diseases; N-(1-(5-chloropyridin-2-yl)-1-(3-fluoro-5-(trifluoromethyl)phenyl)-2-phenylethyl)-4-(trifluoromethyl)thiazol-2-amine; Alzheimer's, atherosclerosis, venous thrombosis, peripheral vascular disease |
| 07/12/2007 | US20070161684 3-Aminocarbonyl, 6-phenyl substituted pyridine-1-oxides as p38 kinase inhibitors |
| 07/12/2007 | US20070161683 Certain chemical entities, compositions, and methods |
| 07/12/2007 | US20070161682 Using 2-(((-4-x, 3,5-dimethylpyridin-2-yl)methylthio)5-methoxy-1H-benzimidazole where x is a leaving group; oxidation using titanium complex catalyst and base |
| 07/12/2007 | US20070161681 Ether derivatives useful as inhibitors of pde4 isozymes |
| 07/12/2007 | US20070161680 {1-Methyl-5-[2-(5-trifluoromethyl-1H-imidazol-2-yl)-pyridin-4-yloxy]-1H-benzoimidazol-2-yl}-(4-trifluoromethyl-phenyl)-amine; inhibitors of kinase/ Raf kinase activity associated with tumorigenesis, serine/threonine kinase or receptor tyrosine kinase; cancer; tumors; inhibitMAPK signaling pathway |
| 07/12/2007 | US20070161679 Method and compositions for the intravenous administration of compounds related to proton pump inhibitors |
| 07/12/2007 | US20070161678 Methods for the synthesis of pyridoxamine |
| 07/12/2007 | US20070161677 Bisarylurea derivatives |
| 07/12/2007 | US20070161676 {1-[4-(3-Pyrrolidin-1-ylpropoxy)phenyl]-1H-indol-2-yl}methanol; inflammation, migraine, motion sickness, pain, Parkinson's Disease, epilepsy, cardiovascular disease (i.e. hyper or hypotension, acute myocardial infarction), gastrointestinal disorders; cognitive disorders |
| 07/12/2007 | US20070161675 Processes for hydrazine addition to acrylic macromonomers and products therefrom |
| 07/12/2007 | US20070161674 Useful in causing mitotic arrest and cell death; (cis,trans)-1-cyclopentyl-4-phenyl-5-(phenylcarbonyl)(3-piperidyl)phenyl ketone |
| 07/12/2007 | US20070161673 P38 kinase inhibitors |
| 07/12/2007 | US20070161672 Compounds |
| 07/12/2007 | US20070161671 7-Azaindoles and the use thereof as therapeutic agents |
| 07/12/2007 | US20070161670 Process for the preparation of substituted heterocycles |
| 07/12/2007 | US20070161669 Benz-indole and benzo-quinoline derivatives as prodrugs for tumor treatment |
| 07/12/2007 | US20070161668 Di-ester prodrugs of camptothecin, process for their preparation and their therapeutical applications |
| 07/12/2007 | US20070161667 Process for preparing inhibitors of nucleoside metabolism |
| 07/12/2007 | US20070161666 Pyrrolo[2,3-d]pyrimidine compounds |
| 07/12/2007 | US20070161665 Cancer treatment method |
| 07/12/2007 | US20070161664 Therapeutic compounds |
| 07/12/2007 | US20070161663 Agents for treating migraine |
| 07/12/2007 | US20070161662 6-Arylmethyl-substituted pyrazolopyrimidines |
| 07/12/2007 | US20070161661 Crystalline N-(4-(4-ammoniumthieno[2,3-d]pyrimidin-5-yl)phenyl)-N'-(2-fluoro-5-(trifluoromethyl)phenyl)urea ethanesulfonate |
| 07/12/2007 | US20070161660 Crystalline N-(4-(4-ammoniumthieno[2,3-d]pyrimidin-5-yl)phenyl)-N'-(2-fluoro-5-(trifluoromethyl)phenyl)urea maleate |
| 07/12/2007 | US20070161659 Crystalline N-(4-(4-ammoniumthieno[2,3-d]pyrimidin-5-yl)phenyl)-N'-(2-fluoro-5-(trifluoromethyl)phenyl)urea benzenesulfonate |
| 07/12/2007 | US20070161658 Crystalline N-(4-(4-ammoniumthieno[2,3-d]pyrimidin-5-yl)phenyl)-N'-(2-fluoro-5-(trifluoromethyl) phenyl)urea camphorsulfonate |
| 07/12/2007 | US20070161657 Crystalline N-(4-(4-aminothieno[2,3-d]pyrimidin-5-yl)phenyl)-N'-(2-fluoro-5-(trifluoromethyl)phenyl)urea hydrobromide |
| 07/12/2007 | US20070161656 N-(4-(4-aminothieno[2,3-d]pyrimidin-5-YL)phenyl)-N'-(2-fluoro-5-(trifluoromethyl)phenyl)urea crystalline form 2 |
| 07/12/2007 | US20070161654 e.g. 5-methyl-3-phenyl-4-(1-phenyl-1H-imidazol-4-yl)-isoxazole; GABA A alpha 5 receptor inverse agonist; cognition activator, Alzheimer's disease |
| 07/12/2007 | US20070161653 Pyrazolo-Pyridine Derivatives As Antiherpes Agents |
| 07/12/2007 | US20070161651 Tie-2 modulators and methods of use |
| 07/12/2007 | US20070161650 4-[2-(4'-Fluoro-biphenyl-4-yloxy)-acetylamino]-thiophene-3-carboxylic acid, a G protein coupled receptor(HM74A) activator, for the treatment and/or prevention of diseases such as increased lipid and cholesterol levels; side effect reduction |
| 07/12/2007 | US20070161649 e.g. 6-Methoxy-(4-benzylpiperidinyl)-indole-5-carboxamide-3-glyoxalic acid; antiinflammatory, antiproliferative agent; neurodegenerative diseases |
| 07/12/2007 | US20070161648 Substituted dihydro-isoindolones useful in treating kinase disorders |